Bio Essence Corp (BIOE)
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Last price
- $0.47
- As of
Kresmion compiles this page from BIOE's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Bio Essence Corp (BIOE): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-23.
See the full BIOE dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for BIOE on one page. Preview it with sample data, then open it live with a free account.
Preview the BIOE dossierActive events for BIOE
No recent events on BIOE in the last 180 days.
FREE, NO ACCOUNT
Every event on BIOE, as it fires
New filings, 13F moves and cross asset events on BIOE land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter.
Recent SEC filings, BIOE
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
Going concern statement
BIOE's 10-Q filed Aug 14, 2026 states:
These conditions raise substantial doubt about the Company's ability to continue as a going concern.
Read the 10-Q on SEC EDGAR Every company with a going concern statement
More data on BIOE
BIOE against its peers
BIOE's operating margin of 47.4% ranks in the 96th percentile of 12 Drug Manufacturers - Specialty & Generic sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | BIOE | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 1.9M USD | 33.7M USD | 15 | 16 |
| Revenue YoY | 485.8% | n/a | n/a | 3 |
| Gross margin | 75.3% | 43.7% | 95 | 10 |
| Operating margin | 47.4% | -18.1% | 96 | 12 |
| Net margin | 47.2% | -25.0% | 97 | 14 |
| Return on equity | n/a | -26.6% | n/a | 14 |
| P / E | 23.5x | n/a | n/a | 1 |
Peers (18): ETST, SHPH, CPHI, MRMD, PLNH, ITHUF, IXHL, INIS, RAPH, HYEX, RMTI, CXXIF, TXMD, AYTU, SCYX, LEEEF, BFRI, TLPH. Left out: MCUJF (period gap), HSTI (period gap), ROMJF (no annual filing), CPIVF (no annual filing), CYPA (no annual filing), OPTH (no annual filing), INCR (period gap). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (BIOE: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in BIOE on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on BIOE in the last 180 days.
Upstream: SEC EDGAR filings for BIOE
Kresmion, "Bio Essence Corp (BIOE) institutional holdings and SEC filings", data as of 2026-10-23, https://kresmion.com/research/BIOE. Upstream data: SEC EDGAR filings for BIOE.
Link to this data (HTML):
<a href="https://kresmion.com/research/BIOE">Bio Essence Corp (BIOE) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow BIOE on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to BIOE for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.